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Abstract
Many international and national authorities recommend that cardiovascular risk assess-
ment using multivariate risk scores be used to identify individuals at high risk of cardio-
vascular disease (CVD). This approach is likely to assure that resources in developing 
countries are allocated to those who need it most. However, not many developing coun-
tries have implemented this approach and different countries have varying progresses in 
adopting the concept. While many developing countries solely described estimated car-
diovascular risk by applying existing CVD risk scores to their population’s cross-sectional 
data, a number of countries have validated and recalibrated existing risk scores and only 
a few have developed new risk scores specific to their populations. To enhance the adop-
tion of such a policy in developing countries, new CVD risk prediction charts for low- and 
medium-resource settings were developed and endorsed by the WHO and International 
Society of Hypertension. However, a number of issues need to be addressed, includ-
ing development of population-specific risk scores, recalibration of available risk scores 
and uncertainty over cost-effectiveness of CVD risk assessment in developing countries. 
Although this high risk approach might represent an effective and practical strategy for 
developing countries, a complementary population-based approach is also needed to 
maximize benefits for CVD prevention.
Keywords: cardiovascular disease, risk assessment, prediction, primary prevention, 
developing countries
1. Introduction
Quantitative assessment of cardiovascular risk has become part of strategies for prevention 
of cardiovascular disease (CVD) in many countries [1, 2]. Many international and national 
authorities have recommended that cardiovascular risk assessment using multivariate risk 
scores be used to identify individuals at high risk of cardiovascular disease, to whom pre-
ventive interventions can be targeted [3–6]. This high-risk approach has been advocated and 
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 routinely used in many developed countries [7, 8]. However, it has not been frequently used 
in developing countries. This chapter summarizes evidence on cardiovascular risk assess-
ment in developing countries by (i) describing the overall rationale for using cardiovascular 
risk scores; (ii) systematically reviewing the literature on cardiovascular risk scores that have 
been developed, validated and/or practically used in developing countries; (iii) exploring 
issues surrounding the utility of the cardiovascular risk scores in these countries; and (iv) 
limitations and implications for alternative approaches.
2. Concept and rationale for cardiovascular risk assessment
Observational studies have shown a positive continuous association between traditional 
cardiovascular risk factors and CVD risk [9–11]. For example, results from the Prospective 
Studies Collaboration, a meta-analysis of almost 900,000 healthy men and women in 61 pro-
spective observational studies, show a linear, continuous relationship between serum total 
cholesterol and the risk of death from ischemic heart disease. Similar associations were also 
held true for each of other traditional risk factors such as blood sugar [10] and blood pres-
sure [11]. This underlines the importance of efforts to address each individual risk factor for 
prevention of cardiovascular disease.
However, there is evidence that clustering of risk factors confers higher levels of CVD risk 
than each individual risk factor. Evidence from observational prospective studies suggests 
that a small effect of an individual risk factor on CVD risk could be magnified in the presence 
of other risk factors [10, 12, 13]. In other words, an individual with mildly abnormal levels of 
several risk factors often has a greater absolute CVD risk than someone with a raised level of 
one risk factor. For example, data from the EPIC-Norfolk cohort revealed that CVD risk could 
vary up to 30-fold in people with the same levels of traditional CVD risk factors, such as cho-
lesterol and blood pressure, but different abnormalities in other risk factors [10] (Figure 1). 
Figure 1. Absolute rates of cardiovascular events over 10 years in individuals with different levels of CVD risk factors in 
EPIC-Norfolk [10] (n = 10,144), Reference group: non-smoking women aged ≤ 55 years with a SBP of ≤ 140 mm Hg and 
an HbA
1c
 ≤ 6.0%, *p < 0.001, Reproduced with approval from Diabetologia.
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The combined effect of risk factors on absolute risk of CVD underlines the importance of 
using multivariate risk prediction tools.
Randomized controlled trials have confirmed that treatment with lipid-lowering medica-
tion reduces the risk of ischemic heart disease and stroke, regardless of pre-treatment blood 
cholesterol levels or other characteristics of the study participants. Overall, there was a 19% 
reduction in coronary mortality for each 1 mmol/L reduction of low density lipoprotein (LDL) 
cholesterol [14]. Similarly, trial evidence suggests that blood pressure-lowering drugs reduce 
the risk of developing CVD events with comparable relative risk reductions at different 
pre-treatment levels of blood pressure [15]. This suggests that substantial benefits could be 
achieved from modifying these risk factors at any starting level in individuals whose absolute 
CVD risk is high for whatever aetiological reason. The concept of treating individuals with 
a disease diagnosed by a threshold of one single risk factor, e.g. diabetes, hypertension or 
hypercholesterolemia, has thus been challenged [12, 16].
Key question is how we can identify those at high CVD risk, which preventive interven-
tions could be targeted. Compelling evidence points out that absolute risk assessment, 
based on the combined effect of multiple risk factors, is likely to be an approach of choice. 
Compared with multifactorial CVD risk assessment, major CVD risk factors such as blood 
pressure or blood lipid levels are, individually, poorer predictors of future CVD risk and 
of the benefits of treatment in individuals with and without existing CVD [1, 10, 16]. In 
addition, primary prevention informed by multifactorial CVD risk assessment is likely to 
prevent a similar number of cardiovascular events at a possibly lower cost than a single-
factor approach [17].
There are a number of reasons why it may be important to quantify the risk of developing car-
diovascular disease (Table 1). The clear rationale for the development of a risk score is critical 
to how its validity is assessed and how it is used.
First, risk scores may be used to rank individuals and groups according to their absolute 
cardiovascular risk so that preventive interventions for those at greatest risk could be tar-
geted [1, 7]. Concerning this purpose, it is the ranking that is important and not necessarily 
the absolute risk estimates. The ranking of absolute CVD risk is clearly essential for making 
collective decisions about treatment and preventive interventions in the population. This is 
rather important for the government/public health professionals, whose decision-making will 
be done based on such information alongside careful consideration on costs incurred and pos-
sible harms from screening and subsequent preventive interventions.
Additionally, risk assessment is also used as a tool to provide prognostic information or esti-
mation of the possible absolute benefits from therapeutic/preventive interventions. In this 
case, accurate estimation of the absolute risk is crucial. An estimate of absolute CVD risk 
can inform the potential for absolute risk reduction, which provides patients with an idea of 
expected benefit from a therapy or intervention. This is more relevant to individual, rather 
than collective, decision-making. However, further research is needed to understand the pro-
cess by which the clinician and patient interact once cardiovascular risk has been assessed. 
Providing CVD risk estimates to doctors and patients may improve perceived CVD risk and 
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medical prescribing particularly in high-risk groups [18]; however, there is no strong evi-
dence that a CVD risk assessment performed by a clinician helps to improve CVD-related 
health outcomes [8].
Finally, the principle justification for calculating cardiovascular risk as part of a preventive 
strategy is to motivate individuals to adhere to favourable behaviour modification and medi-
cal treatments. Apparently, two unchangeable risk factors, age and sex, contribute most to 
the predictive value of a CVD risk score. However, it may be difficult to persuade patients to 
change their behaviour using CVD risk scores that are mostly driven by risk factors that they 
cannot change. Risk scores which incorporate modifiable risk factors may be more useful for 
preventive strategies. That is, it may be important to use risk scores comprised of modifiable 
risk factors rather than using a score dominated by fixed parameters [7]. This approach is of 
particular interest as lifestyle risk factors, such as inadequate physical activity, poor dietary 
habits and adiposity, have been reported to deteriorate blood pressure, serum cholesterol and 
glucose-insulin homeostasis and also associated with novel cardiovascular risk factors such 
as endothelial function and inflammatory markers[19].
3. Development and utility of CVD risk scores in developing countries
Although cardiovascular risk assessment is recommended by many authorities, it has not 
been widely and routinely implemented in developing countries. This may be explained by 
a number of reasons. First, a small number of existing risk scores were originally developed 
in developing countries. Most CVD risk scores were derived from European descent popula-
tions in developed countries, whose background CVD risk may be significantly different from 
that in developing countries. For example, CVD risk scores developed in a relatively high-risk 
Rationale Examples of utility of cardiovascular risk assessment in practice
Risk stratification To rank individuals according to CVD risk and identify those at high risk for preventive 
interventions
The Government makes decision if providing preventive intervention to a certain proportion 
of the population is affordable and acceptable.
Prognostication To provide prognostic information to an individual, e.g. an individual is informed about how 
likely he/she will develop cardiovascular disease in the next 10 years
To provide possible absolute benefits from therapeutic/preventive interventions, e.g. a doctor 
can discuss with his/her patients about to what extent that their CVD risk will reduce if they 
adhere to treatment and achieve certain therapeutic goals
Primary prevention To motivate an individual to modify health behaviours or adhere to treatment, i.e. when a 
patient know smoking and high cholesterol contributes much to increased CVD risk, he/she 
may be more encouraged to stop smoking, adopt healthy diet or regularly take statins
Monitoring CVD risk over time, e.g. information on favourable changes in absolute CVD risk 
after an individual has adopted a healthy lifestyle will help enhance adherence to such a lifestyle.
Table 1. Overall rationale for cardiovascular risk assessment.
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population, such as Framingham risk equations, will overestimate the absolute risk when 
applied to a novel population with a lower background CVD risk [20]. This phenomenon 
emphasizes that recalibration should be done before using such a risk score in a new popu-
lation. However, a few developing countries have carried out recalibration of available risk 
scores partly because a small number of prospective cohorts are available in these countries 
and populations. Further, there is still debate over the cost-effectiveness of implementation of 
such an approach in developing countries. This may have affected policy decision concerning 
cardiovascular risk assessment in these resource-constrained countries.
A different approach was taken to overcome problems regarding the validity of using avail-
able risk scores in a novel population in developing countries. Using epidemiologic survey 
data from the Comparative Risk Assessment Project and the Asia Pacific Cohort Studies 
Collaboration, the WHO and International Society of Hypertension (ISH) developed CVD 
risk prediction charts specific to low- and medium-resource countries in 14 different WHO 
sub-regions, based on age, sex, systolic blood pressure, presence of type 2 diabetes mellitus, 
smoking status and total serum cholesterol levels (Figure 2) [21, 22]. They also developed 
a non-laboratory-based version of the risk prediction charts, which can be used in settings 
where measurement of blood cholesterol is not feasible.
Developing countries have different progresses in adopting the concept of cardiovascular 
risk assessment (Table 2). Some developing countries have only applied existing risk scores, 
namely Framingham risk equations, SCORE and WHO/ISH CVD risk prediction charts, 
Figure 2. WHO/ISH risk prediction chart for Africa Sub-region D, 10-year risk of a fatal or non-fatal cardiovascular 
event by gender, age, systolic blood pressure, total blood cholesterol and smoking status in people without diabetes, 
Reproduced with approval from the WHO  [22].
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to cross-sectional risk factor data to obtain estimated CVD risk and describe the burden of 
high absolute CVD risk in the population. For example, low prevalences of high CVD risk 
according to the WHO/ISH CVD risk prediction charts were observed in many developing 
countries such as Saudi Arabia, Nigeria, Iran, Pakistan, Nepal, Sri Lanka and Cambodia, with 
lower than 10% of the populations being considered high CVD risk [21, 23].
Other countries carried out a validation study to see if the existing risk scores performed well 
in predicting cardiovascular events in its population and further recalibrated the risk scores 
[24–26]. For example, the office-based Framingham risk equations were recalibrated in 46,674 
participants in the Golestan Cohort in North-East of Iran and the authors found that the risk 
score performed reasonably well in predicting CVD mortality (aROC of 0.76–0.79) and over-
estimated CVD risk in men [25]. The SCORE was validated against CVD mortality in Central 
and Eastern Europe and former Soviet Union countries, using prospective data from the 
WHO MONICA project and HAPIEE study. In the MONICA cohort, the SCORE showed only 
moderate discriminatory ability (aROC of 0.54–0.69) and good calibration in Czech Republic, 
Poland and Lithuania, but overestimation of fatal CVD in Russia [26].
A few developing countries have derived new CVD risk scores specific to their populations; 
these include China, Thailand and Malaysia. Using data on 9903 men and women participat-
ing in the USA-PRC Collaborative Study of Cardiovascular Epidemiology Cohort, a new CVD 
risk score was developed based on age, systolic blood pressure, serum total cholesterol, body 
mass index, current smoking status and diabetes mellitus [27]. The risk score was validated 
in another large Chinese cohort with good predictive ability. In Thailand, CHD risk score 
was developed using data from a cohort of workers of the Electric Generating Authority of 
Thailand, [28] and this multivariate risk score has been endorsed to use in patients with and 
without diabetes, and a simpler approach using presence or absence of CVD risk factors is 
recommended for population screening. Based on cost-effectiveness evidence, cardiovascu-
lar risk assessment using multivariate risk scores has recently been endorsed as part of the 
Universal Health Coverage Benefit Package [29]. However, there is no clear evidence about to 
what extent this approach has been adopted in clinical practice.
4. Issues surrounding the utility of CVD risk scores
Cardiovascular risk scores have been widely used in Western countries for almost 20 years 
and were introduced at a time when the cost of cholesterol-lowering drugs was an important 
Describing estimated CVD risk and 
the burden of high CVD risk in its 
population
Validation and recalibration of 
existing risk scores in its population
Developing a new CVD risk score 
specific to its population
Saudi Arabia, Mozambique, Jamaica, 
Pakistan, Sri Lanka Nepal, Mongolia, 
Cambodia
Greece, Iran, Czech Republic, Poland, 
Lithuania, Russia
China, Thailand, Malaysia
Table 2. Examples of developing countries that have adopted concept of cardiovascular risk assessment.
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political issue. International and national recommendations have specified cardiovascular 
risk thresholds that are considered justification for prescribing therapy. As these figures were 
based largely on the proportion of the population requiring treatment and the total cost of 
treatment, it is therefore uncertain if all health systems, particularly in developing countries, 
can afford such a policy.
4.1. Laboratory‐ versus non‐laboratory‐based CVD risk assessment
While most CVD risk assessment tools were based on a set of cardiovascular risk factors 
including laboratory factors such as cholesterol, a number of risk scores including simple or 
routinely available risk factors may be more relevant and applicable to developing countries, 
where laboratory testing is unavailable. Of note, it has been demonstrated in many stud-
ies that laboratory- and non-laboratory-based CVD risk assessments are similarly effective 
at predicting future cardiovascular disease [30–32]. A modelling study based on data from 
the EPIC-Norfolk cohort and published evidence on effectiveness of key preventive inter-
ventions clearly suggests that inviting individuals at high risk identified using routine data 
for a vascular risk assessment could prevent a similar number of new cardiovascular events 
with potential cost-saving, compared to inviting all individuals for laboratory-based CVD 
risk assessment [33]. Cost-effectiveness analyses confirm that single-stage or multi-stage non-
laboratory-based CVD risk assessment had a more attractive cost-effectiveness ratio or ICER 
than a laboratory-based Framingham risk-based approach, as reflected by lower estimated 
costs and higher QALYs [34].
4.2. Are population‐specific risk scores needed?
The most commonly used cardiovascular risk score was originally developed in 5,573 men 
and women participating in the Framingham study in the early 1970s, which generally per-
forms well in North America, but have reportedly performed less well in other populations. 
An alternative to attempting to find a universal risk score that will work in all populations 
may be to develop or recalibrate population-specific risk assessment tools.
Is it worth developing a new risk score which best suits with a new population or trying to 
improve the ability of the existing risk score to predict future disease events by including 
novel risk factors? The answer is likely to be ‘No’ for developing countries. Developing a new 
CVD risk score for developing countries or recalibrating existing risk scores in these countries 
may not be practical as it requires a prospective cohort to develop and validate the risk equa-
tions. A lack of prospective cohorts in developing countries will also limit the opportunities 
to recalibrate the existing risk scores in these countries/populations. Furthermore, including 
novel risk factors, such as biomarkers or genetic information, to a risk score with traditional 
CVD risk factors adds little to the predictive ability at disproportionately considerable costs 
[35, 36]. This may be too expensive for clinical practice in both developed and developing 
countries. Furthermore, there is rarely evidence that reductions in any of these novel markers 
will lower cardiovascular risk [37]. Therefore, rather than attempting to develop a new risk 
assessment tool, it may be more beneficial to make sure that existing risk assessment tools are 
used more broadly and routinely throughout clinical practice.
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However, there remains a paradox of practice concerning CVD risk assessment in develop-
ing countries. While a population specific CVD risk score may be needed, a lack of prospec-
tive cohorts in developing countries prevent them from recalibrating available risk scores 
or developing a new one. While emphasis should be put on using existing risk scores more 
broadly and routinely, these risk scores seem to perform poorly in the developing countries 
and may lead to misclassification of individuals who do and do not require treatments.
4.3. Is universal CVD risk assessment in developing countries cost‐effective?
As screening for high-risk individuals using CVD risk scores always comes with costs related 
to screening itself and subsequent preventive interventions, whether it is cost-effective in set-
tings of resource-scarce countries is an important concern. With limited resources, it might be 
sensible to focus preventive efforts on those who will benefit most. Furthermore, the ratio of 
costs to benefits will be more favourable in individuals where the benefits are larger and this 
approach usually leads to manageable numbers of individuals.
CVD risk stratification will enable the government to use resources in a highly efficient 
way. Different thresholds for starting intensive preventive interventions may be applied to 
countries with different resources. For example, the WHO recommends that a 10-year CVD 
risk threshold of 30–40% may be used in medium- and low-resource countries [38]. When 
applying a WHO-ISH CVD risk prediction charts to randomly selected individuals from 
a number of developing countries such as Nigeria, Iran, China, Pakistan, Georgia, Nepal, 
Cuba and Sri Lanka, adopting WHO recommended 30% CVD risk threshold would help 
reduce healthcare expenditure by avoiding unnecessary drug treatment and thus reducing 
drug costs [21]. As equipment and facilities for CVD risk screening in developing coun-
tries may be limited, the WHO and International Society of Hypertension in 2002 proposed 
a simple approach to cardiovascular risk stratification based on history, blood pressure 
measurement and selective urine analysis for those with systolic/diastolic blood pressure 
of ≥140/90 mmHg [39]. Also, the WHO proposed different scenarios of CVD risk manage-
ment which may be suitable to set with different diagnostic and therapeutic facilities and 
resources (Table 3).
However, it remains uncertain if universal CVD risk screening is cost-effective for resource-
constrained settings in developing countries. In Thailand, cardiovascular risk assessment 
using a population-specific risk score is recommended for men and women aged 35 years and 
above at five-year intervals. The corresponding budget impact analysis shows that such an 
approach was financially feasible for the Thai setting, with the incremental cost-effectiveness 
ratio below the country’s ceiling threshold of USD 4530/QALY [29]. In the contrary, a model-
ling study in Malaysian population suggests that universal screening would result in screen-
ing an additional 7169 individuals, with an incremental cost of USD 115,033 for detection 
of one additional high-risk individual in comparison to targeted screening of those aged 35 
years and above [40]. Further, incremental cost and impact of detection of high-risk indi-
viduals would be higher for women than men for both universal screening and screening 
specific age groups. The authors suggested that targeted gender- and age-specific screening 
strategies would ensure more optimal use of limited resources compared to the country’s 
policy recommendations of universal screening [40].
Recent Trends in Cardiovascular Risks64
4.4. Preventive interventions following CVD risk assessment
There are challenges concerning preventive interventions following CVD risk assessment. 
Different preventive interventions, ranging from lifestyle modification to medication, are 
recommended for individuals or groups with different levels of absolute CVD risk. For 
example, healthy diet, adequate physical activity and weight control should be encouraged 
in all individuals, and monitoring of CVD risk profiles every 3-6 months, nicotine replace-
ment therapy, giving statins in those with an absolute 10-year risk of ≥20%, and prescrib-
ing antiplatelet drugs in those with a 10-year risk of ≥30% [41]. However, there remains 
unclear whether such differential interventions can be implemented in developing coun-
tries, where basic infrastructure and resources for preventive interventions in primary care 
may be lacking.
5. Limitations and implications for alternative approaches
Although identifying individuals or groups at high risk using multivariate CVD risk scores 
is beneficial, the ‘population-based’ strategy, which aims at reducing risk in the entire 
population, regardless of each individual’s level of risk and potential benefits, may also 
be needed. Ability of CVD risk scores to identify individuals at high risk is a key to effec-
tive high-risk strategies. It may be more effective to concentrate our efforts and resources 
where the need, and therefore the benefit, is likely to be greatest. Interventions are also 
Resource availability Scenario 1 Scenario 2 Scenario 3
Human resource Non-physician health 
workers
Medical doctor or specially 
trained nurse
Medical doctor with access to full 
specialist care
Equipment Stethoscope, blood 
pressure measurement 
device, measuring tape or 
weighing scale
Stethoscope, blood 
pressure measurement 
device, tape and weighing 
scale, test tubes, holder, 
burner, solution or test 
strips for checking urine 
glucose and albumin
Stethoscope, blood 
pressure measurement 
device, tape and weighing 
scale, electrocardiograph, 
ophthalmoscope, urine analysis, 
blood analysis: fasting blood 
sugar, electrolytes, creatinine, 
cholesterol and lipoproteins
Optional: test tubes, holder, 
burner, solution or test strips 
for checking urine glucose
Generic drugs Essential: thiazide diuretics Thiazide diuretics, Beta 
blockers, Angiotensin 
converting enzyme 
inhibitors, calcium channel 
blockers (sustained release 
formulations) (Reserpine 
and methyldopa if the 
above anti-hypertensives 
are unavailable), Aspirin, 
Metformin (for refill)
Thiazide diuretics, Beta blockers, 
Angiotensin converting enzyme 
inhibitors, calcium channel 
blockers (sustained release 
formulations) (Reserpine and 
methyldopa if the above anti-
hypertensives are unavailable), 
Aspirin, Insulin, Metformin, 
Glibenclamide, Statins (if 
affordable) Angiotensin receptor 
blocker (if affordable)
Optional: metformin (for 
refill)
Table 3. Three scenarios for CVD risk assessment for setting with different resource availability, adapted from WHO 
CVD risk management package for low and medium resource settings [38].
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matched well with the needs of individuals, probably resulting in better motivation and 
compliance to medications or behaviour change [42]. However, the benefits of the high-
risk approach are limited to a minority of the population. Further, a high-risk strategy 
demands that individuals change eating, smoking and physical activity habits that may 
be largely shaped and constrained by social norms (e.g. to eat differently from family and 
friends), and may thus be seen as ‘behaviourally inappropriate’. As this approach does 
not seek to address the underlying causes of health problems in the population, it is only 
palliative and temporary [43]. The high-risk approach was described by Geoffrey Rose as 
‘no more than an expensive rescue operation, offering disappointingly little towards solv-
ing the overall problem’, so it cannot be the sole means for prevention of cardiovascular 
disease [42].
Given compelling evidence that more cases of cardiovascular disease arise from a larger num-
ber of people at low risk than the smaller number of people at high risk, it might be more 
beneficial to shift the whole distribution of risk factors, such as body mass index, cholesterol 
or blood glucose, in the population in a favourable direction (population-based strategy). This 
phenomenon is commonly observed for diseases where the association of the disease with 
risk factors is linear or curvilinear, while the population distribution of these risk factors is 
approximately normal. For example, Emberson et al. demonstrated that small reductions in 
the population distribution of cardiovascular risk factors (total cholesterol and systolic blood 
pressure) might prevent similar or more CVD events than a strategy focusing preventive 
efforts on those at highest risk [44]. Therefore, in addition to a high-risk approach, there may 
be an important role for a ‘population-based approach’ to shift the population distribution of 
CVD risk factors.
In practice, balanced implementation of the high-risk and population-based approaches for 
CVD prevention is likely to be necessary [2]. Within resource-constrained health service sys-
tems in developing countries, the high-risk preventive strategies, which focus efforts on those 
at highest risk, may be seen as a feasible and cost-effective means of prevention. However, 
complementary population-based preventive strategies are also needed to address the cause 
of the disease incidence in the population.
In conclusion, CVD risk stratification in developing countries will assure that limited resource 
be allocated to individuals or groups who need it most. In developing countries, the clear 
rationale for cardiovascular risk assessment is crucial. The main rationale for cardiovascular 
risk assessment includes ranking individuals according to absolute cardiovascular risk for 
the purpose of targeting therapy to those at greatest risk, providing prognostic information 
or accurate estimation of the likely benefits from preventive/therapeutic interventions, and 
motivating individuals to change their behaviours and adhere to treatments. As not many 
developing countries have adopted this approach, a number of issues need to be addressed, 
including development of population-specific risk scores, recalibration of available risk scores 
and uncertainty over cost-effectiveness of CVD risk assessment in developing countries. 
Although this high-risk approach appears to be effective and practical for developing coun-
tries, a complementary population-based approach is needed to maximize benefits for CVD 
prevention.
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